Biomarkers of Inflammation and Other Factors Associated with COVID-19 Severity in Patients Hospitalized at CHUYO to Implement a Preclinical Trial of a Phytomedicine

Abstract

Aims: SARS-Cov-2 is an RNA virus from the coronavirus family. Most people affected by this new coronavirus have mild illnesses and recover from them. However, the infection can progress to a serious form which can lead to the death of the patient. Study Design: The objective of our work was to identify biomarkers of inflammation and other factors associated with the severity of COVID-19 infection in Yalgado Ouedraogo University Hospital Center (Burkina Faso). Place and Duration of Study: A total of 145 patients were included in our study. Methodology: This was a cross-sectional study with retrospective collection for descriptive and analytical purposes ranging from November 30, 2020, to December 31, 2022, which concerned patients hospitalized at the Yalgado OUEDRAOGO University Hospital Center for COVID-19 infection. Results: The pulmonology department represented 81.38% of hospitalized patients and the intensive care unit 18.62%. Acute respiratory distress syndrome, abnormal leukocyte count, hyperleukocytosis, lymphopenia, lymphocytosis, neutrophilia and, neutrophil/lymphocyte ratio greater than 8 were the biological risk factors for death. Conclusion: Identifying severity factors in clinical practice could help clinicians identify patients with a poor prognosis early to reduce COVID-19-related mortality.